EditFrom NeuroLex
Adefovir Dipivoxil
| Name: | Adefovir Dipivoxil |
| Description: | Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment of hepatitis B. It is a failed treatment for HIV. (Wikipedia) Pharmacology: Adefovir dipivoxil a diester prodrug of adefovir. Adefovir is an acyclic nucleotide analog with activity against human hepatitis B virus (HBV). The concentration of adefovir that inhibited 50% of viral DNA synthesis (IC50) in vitro ranged from 0.2 to 2.5 M in HBV transfected human hepatoma cell lines. The combination of adefovir with lamivudine showed additive anti-HBV activity. Mechanism of action: Adefovir dipivoxil is a prodrug of adefovir. Adefovir is an acyclic nucleotide analog of adenosine monophosphate which is phosphorylated to the active metabolite adefovir diphosphate by cellular kinases. Adefovir diphosphate inhibits HBV DNA polymerase (reverse transcriptase) by competing with the natural substrate deoxyadenosine triphosphate and by causing DNA chain termination after its incorporation into viral DNA. The inhibition constant (Ki) for adefovir diphosphate for HBV DNA polymerase was 0.1 M. Adefovir diphosphate is a weak inhibitor of human DNA polymerases and with Ki values of 1.18 M and 0.97M, respectively. Drug type: Approved. Investigational. Small Molecule. Drug category: Antiviral Agents. Reverse Transcriptase Inhibitors |
| Synonym(s): | ADV, Adefovir, Adefovir pivoxil, Adefovirdipivoxl, GS-840, PMEA, adefovir dipivoxil, bis-POM PMEA, Hepsera, Preveon |
| Related to: | P protein (Includes: DNA-directed DNA polymerase |
| Has role: | Drug |
| Super-category: | Molecule |
| URL: | http://www.drugbank.ca/drugs/DB00718 |
| Id: | DB00718 |
| Link to OWL / RDF: | Download this content as OWL/RDF |
Facts about Adefovir DipivoxilRDF feed
| Comment | taken from DrugBank |
| Curator | Ab + |
| DefiningCitation | http://www.drugbank.ca/drugs/DB00718 + |
| Definition | Adefovir dipivoxil, previously called bis- … Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment of hepatitis B. It is a failed treatment for HIV. (Wikipedia) Pharmacology: Adefovir dipivoxil a diester prodrug of adefovir. Adefovir is an acyclic nucleotide analog with activity against human hepatitis B virus (HBV). The concentration of adefovir that inhibited 50% of viral DNA synthesis (IC50) in vitro ranged from 0.2 to 2.5 M in HBV transfected human hepatoma cell lines. The combination of adefovir with lamivudine showed additive anti-HBV activity. Mechanism of action: Adefovir dipivoxil is a prodrug of adefovir. Adefovir is an acyclic nucleotide analog of adenosine monophosphate which is phosphorylated to the active metabolite adefovir diphosphate by cellular kinases. Adefovir diphosphate inhibits HBV DNA polymerase (reverse transcriptase) by competing with the natural substrate deoxyadenosine triphosphate and by causing DNA chain termination after its incorporation into viral DNA. The inhibition constant (Ki) for adefovir diphosphate for HBV DNA polymerase was 0.1 M. Adefovir diphosphate is a weak inhibitor of human DNA polymerases and with Ki values of 1.18 M and 0.97M, respectively. Drug type: Approved. Investigational. Small Molecule. Drug category: Antiviral Agents. Reverse Transcriptase Inhibitors l Agents. Reverse Transcriptase Inhibitors |
| Has role | Drug + |
| Id | DB00718 + |
| Label | Adefovir Dipivoxil + |
| ModifiedDate | 4 February 2010 + |
| RelatedTo | P protein (Includes: DNA-directed DNA polymerase + |
| SuperCategory | Molecule + |
| Synonym | ADV +, Adefovir +, Adefovir pivoxil +, Adefovirdipivoxl +, GS-840 +, PMEA +, adefovir dipivoxil +, bis-POM PMEA +, Hepsera +, and Preveon + |